MiNK Therapeutics, Inc.
INKT
Rank in Stocks
#22506
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing... MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Share Price
$10.30
Last synced: 2026-11-09
Market Cap
$52.54M
Change (1 day)
-0.53%
Change (1 year)
-22.13%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MiNK Therapeutics, Inc. (INKT)
Category
Healthcare
EPS for MiNK Therapeutics, Inc. (INKT)
EPS as of June 2026 TTM: $-2.39
According to MiNK Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.39. At the end of 2025 the company had an EPS of $-2.93, a decrease compared to its 2024 EPS of $-2.90.
EPS history for MiNK Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.39 | -18.43% |
| 2025 | $-2.93 | 1.03% |
| 2024 | $-2.90 | -55.66% |
| 2023 | $-6.54 | -21.30% |
| 2022 | $-8.31 | -7.97% |
| 2021 | $-9.03 | 83.91% |
| 2020 | $-4.91 | -37.05% |
| 2019 | $-7.80 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -755.23% |
US
|
|
| $-7.07 | 195.82% |
US
|
|
| $-5.29 | 121.34% |
AU
|
|
| $12.88 | -638.92% |
BE
|
|
| $21.56 | -1,002.09% |
NL
|
Questions about MiNK Therapeutics, Inc.'s earnings per share (EPS)
What is MiNK Therapeutics, Inc.'s earnings per share (EPS)?
MiNK Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.39, as of Jun 2026.
What was MiNK Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, MiNK Therapeutics, Inc.'s earnings per share (EPS) was $-2.93, compared with $-2.90 in 2024.
How has MiNK Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, MiNK Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-2.90) and lowest in 2021 ($-9.03).
How does MiNK Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
MiNK Therapeutics, Inc.'s earnings per share (EPS) ($-2.39) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.